Sanofi

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. 

CEO
Olivier Antoine M. Charmeil
CEOOlivier Antoine M. Charmeil
Employees
76,493
Employees76,493
Headquarters
Paris, Ile-de-France
HeadquartersParis, Ile-de-France
Founded
1994
Founded1994
Employees
76,493
Employees76,493

SNY Key Statistics

Market cap
106.69B
Market cap106.69B
Price-Earnings ratio
18.31
Price-Earnings ratio18.31
Dividend yield
3.63%
Dividend yield3.63%
Average volume
4.12M
Average volume4.12M
High today
$44.23
High today$44.23
Low today
$43.32
Low today$43.32
Open price
$43.79
Open price$43.79
Volume
2.82M
Volume2.82M
52 Week high
$59.17
52 Week high$59.17
52 Week low
$43.32
52 Week low$43.32

SNY News

Seeking Alpha 13h
Sanofi’s venglustat granted U.S. breakthrough therapy status for type 3 Gaucher disease

The U.S. Food and Drug Administration has granted breakthrough therapy designation to Sanofi’s (SNY) venglustat, a novel, investigational oral glucosylceramide...

Sanofi’s venglustat granted U.S. breakthrough therapy status for type 3 Gaucher disease
TipRanks 1d
Sanofi’s Lunsekimig Asthma Study Completion: What Investors Should Watch Next

Sanofi (SNYNF) announced an update on their ongoing clinical study. The Phase 2b study titled “A Randomized, Double-blind, Placebo-controlled, Parallel-group,...

TipRanks 2d
Regeneron and Sanofi Extend Phase 3 Itepekimab Program in Chronic Sinus Disease

Regeneron Pharmaceuticals (REGN), Sanofi SA (SNY) announced an update on their ongoing clinical study. The study “A Double-blinded Extension Study to Evaluate...

Analyst ratings

67%

of 6 ratings
Buy
66.7%
Hold
33.3%
Sell
0%

More SNY News

TipRanks 4d
Sanofi India Flags Transfer of Dormant Shareholdings to IEPF

Sanofi India Limited ( (IN:SANOFI) ) has provided an announcement. Sanofi India Limited has notified stock exchanges that it has published newspaper advertisem...

Seeking Alpha 6d
Vaxart signals $700M COVID-19 vaccine milestone path as Sanofi partnership advances and 2026 data readouts approach

Earnings Call Insights Vaxart signals $700M COVID-19 vaccine milestone path as Sanofi partnership advances and 2026 data readouts approach Mar. 12, 2026 6:53 PM...

Vaxart signals $700M COVID-19 vaccine milestone path as Sanofi partnership advances and 2026 data readouts approach
TipRanks 6d
Sanofi Targets Real-World Teplizumab Data in Type 1 Diabetes: What Investors Should Watch

Sanofi SA (SNY) announced an update on their ongoing clinical study. Sanofi’s new study, “Long-Term Outcomes of Participants Treated With Teplizumab in Routine...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.